Printer Friendly

Comet Therapeutics Raises USD 28.5m Series A Financing to Support Development of Treatments Built Around Its Novel CoEnzyme A Platform.

M2 PHARMA-June 24, 2019-Comet Therapeutics Raises USD 28.5m Series A Financing to Support Development of Treatments Built Around Its Novel CoEnzyme A Platform

(C)2019 M2 COMMUNICATIONS

- US-based Comet Therapeutics, a company built around the unique ability to re-engineer Coenzyme A -related metabolism, has raised USD 28.5m in series A funding to develop a broad portfolio of drug candidates, the company said.

Previously, the company received seed funding from top tier investors, including original investors Sofinnova Partners and INKEF Capital.

Canaan and existing investor Sofinnova Partners co-led the round, with participation by existing investor INKEF Capital and new investor BioInnovation Capital.

Comet's platform has numerous potential applications including metabolic disorders, neuro-metabolic diseases, immuno-metabolic conditions and other life-threatening diseases.

Previously, Dr. De Graaf was president and CEO of Syntimmune, a development-stage company that Alexion Pharmaceuticals purchased in 2018.

Comet's executives also include chief scientific officer Art Taveras, Ph.D., who has led or contributed to more than 40 small-molecule drug discovery and development programs, and served as vice president of small molecule drug discovery at Biogen.

Co-founder and chief technology officer Enej Kuscer, Ph.D., has worked in CoA metabolism for more than 10 years and has previously co-founded European biotech start-ups including Acies Bio and Whey2Value.

Dr. Van Vlasselaer has started and overseen development and successful exits of many innovative life science companies on the West Coast, including immuno-oncology leader Armo BioSciences, acquired by Eli Lilly and Co. last year for USD 1.6bn; TrueNorth, acquired by Bioverativ; iPierian, acquired by Bristol-Myers Squibb; Arresto Biosciences, acquired by Gilead; and Avidia, acquired by Amgen.

Concurrent with the financing, Comet's board of directors is expanding to include Roel Bulthuis of INKEF Capital; Colleen Cuffaro, Ph.D., of Canaan; Anthony Walsh, Ph.D., of BioInnovation Capital, who are joining existing board members Henrijette Richter, Ph.D., of Sofinnova Partners, Paris; Drs. Ben Machielse, independent director; and Peter Van Vlasselaer, Ph.D., and David de Graaf, Ph.D., president and CEO of Comet.

CoEnzyme A is essential in numerous cellular processes including the metabolism of fatty acids, amino acids and sugars; the regulation of gene expression; mitochondrial health and the proper functioning of the TCA cycle, which provides the energy cells need to live.

CoA dysfunctions play a role in many rare, genetic disorders of metabolism. Dysregulated CoA metabolism is also a key factor in conditions with neuro-metabolic and immuno-metabolic origins.

The CoMET Platform enables precise targeting of specific CoA species to diseased tissues and organelles within cells where these species are depleted, thereby restoring normal cellular metabolism and regulation that underlie basic human health.

Comet Therapeutics is in CoEnzyme A science and intermediate metabolism. Its proprietary CoMET Platform is the foundation of a growing pipeline of next-generation therapeutics to treat conditions in which dysregulated CoA plays a role.

Utilising this science and forging innovative partnerships, Comet aspires to develop and commercialise treatments for patients suffering from metabolic, neurological and immunological disorders.

((Comments on this story may be sent to info@m2.com))
COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jun 24, 2019
Words:501
Previous Article:Japan's MHLW Approves Invivoscribe's LeukoStrat CDx FLT3 Mutation Assay as the CDx for Daiichi Sankyo's Quizartinib for Treatment of...
Next Article:Gamida Cell to commence follow-on public offering of USD30.0m ordinary shares.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters